Jennifer A Shin1, Areej El-Jawahri1, Amanda Parkes2, Stephen M Schleicher3, Helen P Knight4, Jennifer S Temel1. 1. 1 Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center , Harvard Medical School, Boston, Massachusetts. 2. 2 MD Anderson Cancer Center , Houston, Texas. 3. 3 Memorial Sloan Kettering Cancer Center , New York, New York. 4. 4 Johns Hopkins School of Medicine , Baltimore, Maryland.
Abstract
BACKGROUND: Although breast cancer is the second leading cause of cancer-related mortality in women in the United States, few studies focus on the supportive care needs of patients living with metastatic breast cancer (MBC). OBJECTIVE: We studied quality of life (QOL), depression, anxiety, and prognostic understanding of patients with MBC. DESIGN: We conducted a cross-sectional study of 140 patients with MBC, stratified by receipt of endocrine therapy or chemotherapy. MEASUREMENTS: We evaluated anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). We assessed QOL using the Functional Assessment of Cancer Therapy-Breast (FACT-B), specifically measuring the FACT-B Trial Outcome Index (TOI), which includes physical and functional well-being and breast cancer-specific symptoms. Higher FACT-B TOI scores represent better QOL. We used a 12-item questionnaire to assess patients' perceptions of their prognosis and goals of therapy. RESULTS: Compared to those taking endocrine therapy (n = 40), patients receiving chemotherapy (n = 100) reported lower scores on the FACT-B TOI (66.1 versus 72.5, p < 0.01) and more depression symptoms (HADS-D >7; 22% versus 7.5%, p = 0.03). Higher scores on the FACT-B TOI were associated with lower depression (β, -0.16; p < 0.01) and anxiety (β, -0.11; p < 0.01), and patients who reported frequent prognostic conversations with their oncologists had less depression (β, -1.28; p < 0.01). Thirty-nine percent (54/140) reported that their cancer was likely curable. CONCLUSION: Patients with MBC, particularly those treated with chemotherapy, may benefit from interventions to address their physical, functional, and breast cancer-related symptoms. Many do not report accurate prognostic understanding, and more frequent prognostic conversations might address this information gap.
BACKGROUND: Although breast cancer is the second leading cause of cancer-related mortality in women in the United States, few studies focus on the supportive care needs of patients living with metastatic breast cancer (MBC). OBJECTIVE: We studied quality of life (QOL), depression, anxiety, and prognostic understanding of patients with MBC. DESIGN: We conducted a cross-sectional study of 140 patients with MBC, stratified by receipt of endocrine therapy or chemotherapy. MEASUREMENTS: We evaluated anxiety and depression using the Hospital Anxiety and Depression Scale (HADS). We assessed QOL using the Functional Assessment of Cancer Therapy-Breast (FACT-B), specifically measuring the FACT-B Trial Outcome Index (TOI), which includes physical and functional well-being and breast cancer-specific symptoms. Higher FACT-B TOI scores represent better QOL. We used a 12-item questionnaire to assess patients' perceptions of their prognosis and goals of therapy. RESULTS: Compared to those taking endocrine therapy (n = 40), patients receiving chemotherapy (n = 100) reported lower scores on the FACT-B TOI (66.1 versus 72.5, p < 0.01) and more depression symptoms (HADS-D >7; 22% versus 7.5%, p = 0.03). Higher scores on the FACT-B TOI were associated with lower depression (β, -0.16; p < 0.01) and anxiety (β, -0.11; p < 0.01), and patients who reported frequent prognostic conversations with their oncologists had less depression (β, -1.28; p < 0.01). Thirty-nine percent (54/140) reported that their cancer was likely curable. CONCLUSION:Patients with MBC, particularly those treated with chemotherapy, may benefit from interventions to address their physical, functional, and breast cancer-related symptoms. Many do not report accurate prognostic understanding, and more frequent prognostic conversations might address this information gap.
Authors: Areej El-Jawahri; Lara Traeger; Elyse R Park; Joseph A Greer; William F Pirl; Inga T Lennes; Vicki A Jackson; Emily R Gallagher; Jennifer S Temel Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: Alaka Ray; Susan D Block; Robert J Friedlander; Baohui Zhang; Paul K Maciejewski; Holly G Prigerson Journal: J Palliat Med Date: 2006-12 Impact factor: 2.947
Authors: M J Brady; D F Cella; F Mo; A E Bonomi; D S Tulsky; S R Lloyd; S Deasy; M Cobleigh; G Shiomoto Journal: J Clin Oncol Date: 1997-03 Impact factor: 44.544
Authors: Jennifer S Temel; Joseph A Greer; Sonal Admane; Emily R Gallagher; Vicki A Jackson; Thomas J Lynch; Inga T Lennes; Connie M Dahlin; William F Pirl Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544
Authors: Jane C Weeks; Paul J Catalano; Angel Cronin; Matthew D Finkelman; Jennifer W Mack; Nancy L Keating; Deborah Schrag Journal: N Engl J Med Date: 2012-10-25 Impact factor: 91.245
Authors: JoAnne Alissi Cosgriff; Margaret Pisani; Elizabeth H Bradley; John R O'Leary; Terri R Fried Journal: J Gen Intern Med Date: 2007-09-14 Impact factor: 5.128
Authors: J C Weeks; E F Cook; S J O'Day; L M Peterson; N Wenger; D Reding; F E Harrell; P Kussin; N V Dawson; A F Connors; J Lynn; R S Phillips Journal: JAMA Date: 1998-06-03 Impact factor: 56.272
Authors: Rebecca G Hagerty; Phyllis N Butow; Peter A Ellis; Elizabeth A Lobb; Susan Pendlebury; Natasha Leighl; David Goldstein; Sing Kai Lo; Martin H N Tattersall Journal: J Clin Oncol Date: 2004-05-01 Impact factor: 44.544
Authors: Sharon M Parker; Josephine M Clayton; Karen Hancock; Sharon Walder; Phyllis N Butow; Sue Carrick; David Currow; Davina Ghersi; Paul Glare; Rebecca Hagerty; Martin H N Tattersall Journal: J Pain Symptom Manage Date: 2007-05-25 Impact factor: 3.612
Authors: Isamme AlFayyad; Mohamad Al-Tannir; Jude Howaidi; Dana AlTannir; Amani Abu-Shaheen Journal: Qual Life Res Date: 2022-04-30 Impact factor: 3.440
Authors: Kah Poh Loh; Supriya G Mohile; Jennifer L Lund; Ronald Epstein; Lianlian Lei; Eva Culakova; Colin McHugh; Megan Wells; Nikesha Gilmore; Mostafa R Mohamed; Charles Kamen; Valerie Aarne; Alison Conlin; James Bearden; Adedayo Onitilo; Marsha Wittink; William Dale; Arti Hurria; Paul Duberstein Journal: Oncologist Date: 2019-04-23
Authors: Gina Tuch; Chandrika Sanapala; Supriya G Mohile; Paul R Duberstein; Enrique Soto-Perez-de-Celis; Huiwen Xu; Eva Culakova; Marie Flannery; Reza Yousefi-Nooraie; Ronald M Epstein; Colin McHugh; Valerie Aarne; Hannah Kim; Jodi Geer; Mark A O'Rourke; Nicholas J Vogelzang; Kah Poh Loh Journal: Oncologist Date: 2021-08-11
Authors: Marloes E Clarijs; Jacob Thurell; Friedrich Kühn; Carin A Uyl-de Groot; Elham Hedayati; Maria M Karsten; Agnes Jager; Linetta B Koppert Journal: Cancers (Basel) Date: 2021-05-12 Impact factor: 6.639
Authors: Laura B Oswald; Brandy Arredondo; Mika Kadono; Dinorah Martinez-Tyson; Cathy D Meade; Frank Penedo; Michael H Antoni; Hatem Soliman; Ricardo L B Costa; Heather S L Jim Journal: Cancer Med Date: 2021-06-24 Impact factor: 4.452